Department of Dermatology, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, South Korea.
Dermatol Ther. 2020 Nov;33(6):e14520. doi: 10.1111/dth.14520. Epub 2020 Nov 18.
Flushing and erythema are the most common symptoms of rosacea; however, management of these symptoms remains challenging. Recent case studies suggest that treatment with carvedilol may reduce facial flushing and persistent erythema in the pathogenesis of rosacea. To find the effect of carvedilol in the treatment of facial flushing and erythema in rosacea. Twenty-four rosacea patients treated with carvedilol for facial flushing and erythema were retrospectively reviewed. All patients were prescribed carvedilol 6.25 mg either once or twice per day, and the daily dose was gradually titrated up to 12.5 mg. Clinical erythema severity was assessed by the Clinician's Erythema Assessment (CEA) and Patient's Self-Assessment (PSA) scales. Improvement of CEA and PSA scores compared to the baseline were assessed. The proportion of patients with improvement of two or more points from baseline in CEA score was analyzed by sex, previous treatment exposure, disease duration, and subtypes. The mean change of -1.6 in the CEA score and of -1.8 in the PSA score showed significant improvement from baseline. Erythematotelangiectatic rosacea (ETR) patients achieved more than 2-points improvement in the CEA score, compared with non-ETR patients (53.8% vs 16.7% [P = .035]). No statistically significant differences were observed by sex, disease duration, or previous treatment exposure. No serious adverse event was observed. Carvedilol can be an effective and safe treatment option for rosacea patients suffering from facial flushing and erythema.
潮红和红斑是酒渣鼻最常见的症状；然而，这些症状的管理仍然具有挑战性。最近的病例研究表明，卡维地洛治疗可能会减轻酒渣鼻发病机制中的面部潮红和持续性红斑。为了找到卡维地洛治疗酒渣鼻面部潮红和红斑的效果。回顾性分析了 24 例因面部潮红和红斑而接受卡维地洛治疗的酒渣鼻患者。所有患者均给予卡维地洛 6.25mg，每日 1 次或 2 次，每日剂量逐渐增至 12.5mg。临床红斑严重程度通过临床医生红斑评估（CEA）和患者自我评估（PSA）量表评估。评估与基线相比 CEA 和 PSA 评分的改善情况。分析了 CEA 评分改善 2 分或以上的患者比例与性别、既往治疗暴露、疾病持续时间和亚型的关系。CEA 评分平均下降 1.6，PSA 评分平均下降 1.8，与基线相比有显著改善。与非 ETR 患者相比，红斑毛细血管扩张型酒渣鼻（ETR）患者的 CEA 评分改善超过 2 分（53.8% vs 16.7% [P=.035]）。性别、疾病持续时间或既往治疗暴露无统计学差异。未观察到严重不良事件。卡维地洛可能是治疗面部潮红和红斑的酒渣鼻患者的有效和安全选择。
